Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc > Buyout
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by tenbagger_pleaseon Feb 07, 2023 10:42pm
193 Views
Post# 35273513

RE:RE:RE:RE:RE:RE:RE:RE:RE:Buyout

RE:RE:RE:RE:RE:RE:RE:RE:RE:Buyout

Miravo EBITDA will fall off a cliff in a few years with patent expiries.  Do the same table based on 2025 or 2026 EBITDA.   

Read the management information form.  120 parties contacted and 1.35 is the best Mrv could get.  Vote no.... then what?  Stock falls and no one else bids.  Then cash flow starts to fall every year until the company dilutes shareholders to refinance debt.  You won't get better than 1.35.  

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities